Colorectal Cancer

Why trials studying Colorectal Cancer stopped, in this sample of ClinicalTrials.gov.

53 stopped trials with a clear reason; 89% ended for non-scientific reasons.

Trials

• A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
  NCT06091930 · TERMINATED · funding business
  “Sponsor decision”
• Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
  NCT06052852 · TERMINATED · funding business
  “Sponsor decision”
• A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
  NCT05983367 · TERMINATED · futility
  “At the time of the primary analysis, results did not meet the primary endpoint”
• A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
  NCT05678257 · TERMINATED · futility
  “A pre-planned initial analysis concluded that the study was unlikely to achieve its primary objective of demonstrating superior progression-free survival. Based on the Steering Committee's recommendation, the Sponsor has closed the study.”
• Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
  NCT05631574 · TERMINATED · funding business
  “Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure.”
• A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
  NCT05497336 · TERMINATED · funding business
  “company development strategy adjustment”
• A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
  NCT05397171 · TERMINATED · safety
  “This study was terminated early as per protocol Section 4.4, based on overall risk-benefit profile observed to date. No safety concerns reported. Only Substudy 1 Part A was started; Parts B \& C were not started. Entire Master Protocol was terminated.”
• FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
  NCT05395052 · TERMINATED · funding business
  “This study was terminated by the Sponsor.”
• Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
  NCT05194735 · TERMINATED · funding business
  “Funding”
• Magnetic Particle-ICG Lymph Node Mapping in Colorectal Cancer
  NCT05092750 · WITHDRAWN · slow accrual
  “0 accrual”
• Radiation Therapy on Pelvic Floor Disorders in Women
  NCT04623515 · TERMINATED · slow accrual
  “IRB closure, slow accrual”
• The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors
  NCT04696848 · TERMINATED · slow accrual
  “Recruitment difficulty”
• A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
  NCT04682431 · TERMINATED · funding business
  “Sponsor business decision.”
• A Study of PY314 in Subjects With Advanced Solid Tumors
  NCT04691375 · TERMINATED · funding business
  “Sponsor business decision.”
• Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
  NCT04553692 · TERMINATED · funding business
  “Study terminated due strategic corporate pivot to focus on auto-immune indications”
• IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer
  NCT04258111 · TERMINATED · funding business
  “After careful consideration, our company has decided to revise the overall development strategy for IBI310 and discontinue further registration research for this project. Consequently, the ongoing screening process will be terminated, and this decisi”
• A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
  NCT04442126 · TERMINATED · funding business
  “A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.”
• A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer
  NCT04148378 · WITHDRAWN · funding business
  “Company shifted focus”
• A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
  NCT04172597 · TERMINATED · funding business
  “Strategic business decision (unrelated to safety)”
• Anti-PD-1 +/- RT for MSI-H Solid Tumors
  NCT04001101 · WITHDRAWN · logistics pi
  “PI has decided to withdraw the study”
• Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
  NCT04106167 · TERMINATED · funding business
  “This study was terminated by the Sponsor.”
• Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
  NCT03875313 · TERMINATED · slow accrual
  “Slow Enrollment”
• Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101
  NCT03644459 · WITHDRAWN · slow accrual
  “Unable to recruit individuals for the study”
• A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
  NCT03555149 · TERMINATED · slow accrual
  “The Sponsor made the decision to terminate the study due to start up and recruitment issues caused by limited resource availability at the treating centers.”
• REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
  NCT03435640 · TERMINATED · funding business
  “Based on the overall results from the Phase 1 part of the study the sponsor decided to end the study. The decision was not due to safety reasons.”
• Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Metastatic Colorectal Cancer
  NCT03158610 · TERMINATED · slow accrual
  “Difficult to enrollment patient”
• Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
  NCT03070574 · TERMINATED · slow accrual
  “Due to poor patient recruitment and insufficient financing.”
• Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer
  NCT02630420 · WITHDRAWN · funding business
  “The study never officially funded and therefore never began.”
• A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
  NCT02576665 · TERMINATED · funding business
  “Sponsor decision”
• A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection
  NCT02005614 · TERMINATED · slow accrual
  “Unable to recruit patients.”
• Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer
  NCT01856322 · TERMINATED · slow accrual
  “The trial was prematurely closed due to lack of accrual.”
• Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC
  NCT01631539 · WITHDRAWN · slow accrual
  “No patients enrolled”
• A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis
  NCT01523639 · TERMINATED · slow accrual
  “Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.”
• Double-balloon Colonoscopy to Increase Colonoscopy Completion Rate
  NCT01587872 · TERMINATED · slow accrual
  “Slow patient recruitment, not enough patients willing to participate within the prespecified time frame.”
• Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4
  NCT01726309 · TERMINATED · funding business
  “As per the HRBs new funding model, HRBs investment will not support costs associated with routine patient care or translational studies, biobanks, patient registries and questionnaires. Therefore, a decision was made to cease further study follow up.”
• Epidural Versus Patient-controlled Analgesia for Reduction in Long-term Mortality Following Colorectal Cancer Surgery
  NCT01318161 · TERMINATED · slow accrual
  “Difficulty in recruiting”
• Treatment Strategies for Primarily Generalized Colorectal Cancer
  NCT01056809 · TERMINATED · slow accrual
  “Too slow recruitment”
• Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer
  NCT00677924 · TERMINATED · funding business
  “Due to changes in portfolio review”
• Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma
  NCT00625183 · TERMINATED · slow accrual
  “Withdrawn due to poor/low accrual”
• Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer
  NCT00493857 · TERMINATED · funding business
  “Cohort 2 not going forward. Manadate changes in Company”
• Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
  NCT00408772 · WITHDRAWN · slow accrual
  “Lack of accrual”
• Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
  NCT00766142 · TERMINATED · futility
  “In 2008, new data highlighted that Cetuximab had no efficacy in case of KRAS mutation. As such, eligibility criteria were revised and limited to KRAS wild-type. Inclusions were thus slown down considerably, and the trial was stopped.”
• Cholecalciferol and Calcium Carbonate in Treating Patients With Colon Cancer That Has Been Removed by Surgery
  NCT00470353 · TERMINATED · slow accrual
  “Withdrawn due to poor accrual/lack of funding”
• Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer
  NCT00296062 · TERMINATED · slow accrual
  “Trial did not move to Phase II portion due to poor tolerance of treatment”
• MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer
  NCT00602329 · TERMINATED · slow accrual
  “Due to Poor accrual”
• Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer
  NCT00268463 · TERMINATED · slow accrual
  “The study was terminated due to low accrual.”
• Study of XL999 in Patients With Metastatic Colorectal Cancer
  NCT00277303 · TERMINATED · safety
  “Study was terminated due to cardiac toxicities in the subjects”
• Intra-op Lidocaine and Ketamine Effect on Postoperative Bowel Function
  NCT00229567 · TERMINATED · slow accrual
  “insufficient numbers of eligible patients as laparscopic surgery increased and open surgery decreased.”
• Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment
  NCT00538291 · TERMINATED · futility
  “Study was terminated early due to lack of efficacy.”
• Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer
  NCT00087334 · TERMINATED · slow accrual
  “Withdrawn due to poor/low accrual”
• Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer
  NCT00062023 · TERMINATED · funding business
  “Study closed by the NCI.”
• Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
  NCT00006046 · TERMINATED · slow accrual
  “poor recruitment”
• SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
  NCT00005030 · WITHDRAWN · slow accrual
  “No enrollment.”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.